Alaunos Therapeutics, Inc. (TCRT) Earnings History
Net Loss25 years of earnings data (2001–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Alaunos Therapeutics, Inc. (TCRT) Earnings Overview
As of June 22, 2026, Alaunos Therapeutics, Inc. (TCRT) reported trailing twelve-month net income of -$4M, reflecting +24.7% year-over-year growth. The company earned $-2.11 per diluted share over the past four quarters, with a net profit margin of -83520.0%.
Looking at the long-term picture, TCRT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$35,842 in fiscal 2003.
Alaunos Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IOVA (-$354M net income, -148.4% margin), FATE (-$130M net income, -2051.1% margin), TCRX (-$124M net income, -1256.8% margin), TCRT has room to improve margins relative to the peer group. Compare TCRT vs IOVA →
TCRT Earnings vs Peers
Earnings metrics vs comparable public companies
TCRT Historical Earnings Data (2001–2025)
25 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$4M | +10.8% | -$4M | $-2.20 | -83520.0% | -84500.0% |
| 2024 | -$5M | +86.7% | -$5M | $-2.92 | -46790.0% | -48120.0% |
| 2023 | -$35M | +6.9% | -$34M | $-21.97 | -702800.0% | -685340.0% |
| 2022 | -$38M | +52.1% | -$35M | $-25.97 | -1291.2% | -1201.4% |
| 2021 | -$79M | +1.5% | -$78M | $-53.80 | -19786.7% | -19484.7% |
| 2020 | -$80M | +32.1% | -$80M | $-56.42 | - | - |
| 2019 | -$118M | -121.8% | -$58M | $-158.90 | - | - |
| 2018 | -$53M | +2.2% | -$54M | $-55.44 | -36381.5% | -36921.9% |
| 2017 | -$54M | +67.1% | -$53M | $-59.50 | -850.3% | -837.3% |
| 2016 | -$165M | -37.6% | -$165M | $-190.15 | -2409.2% | -2409.4% |
| 2015 | -$120M | -277.9% | -$120M | $-143.63 | -2772.1% | -2772.4% |
| 2014 | -$32M | +44.3% | -$43M | $-47.14 | -2314.7% | -3168.2% |
| 2013 | -$57M | +40.6% | -$58M | $-99.67 | -7138.4% | -7214.1% |
| 2012 | -$96M | -50.7% | -$102M | $-183.58 | -12016.5% | -12771.1% |
| 2011 | -$64M | -95.2% | -$71M | $-144.94 | -9561.9% | -10704.6% |
| 2010 | -$33M | -327.1% | -$25M | $-106.52 | - | - |
| 2009 | -$8M | +69.7% | -$12M | $-49.65 | - | - |
| 2008 | -$25M | +5.2% | -$26M | $-178.25 | - | - |
| 2007 | -$27M | -49.0% | -$29M | $-211.94 | - | - |
| 2006 | -$18M | -87.6% | -$19M | $-213.06 | - | - |
| 2005 | -$10M | -24198.9% | -$10M | $-262.83 | - | - |
| 2004 | $-39,166 | -9.3% | $-39,166 | $-39.44 | - | - |
| 2003 | $-35,842 | +10.3% | $-35,842 | $-18.31 | - | - |
| 2002 | $-39,941 | +44.9% | $-39,941 | $-26.73 | -1554.1% | -1554.1% |
| 2001 | $-72,535 | - | $-72,535 | $-48.55 | -4202.5% | -4202.5% |
Download Data
Export TCRT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TCRT — Frequently Asked Questions
Quick answers to the most common questions about buying TCRT stock.
What is TCRT earnings per share (EPS)?
TCRT trailing twelve-month (TTM) diluted EPS is $-2.11, reflecting +24.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2001 to 2025 is available in the table on this page.
What is Alaunos Therapeutics, Inc.'s net income?
Alaunos Therapeutics, Inc. (TCRT) trailing twelve-month net income is $-4M as of 2025. Earnings grew +24.7% year-over-year.
Is TCRT profitable?
TCRT is not currently profitable on a TTM basis, reporting a net loss of $-4M. Net margin is -83520.0%. Investors should monitor for a return to profitability.
What is TCRT's earnings growth rate?
TCRT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2001 to 2025.
What are TCRT's profit margins?
Alaunos Therapeutics, Inc. net profit margin is -83520.0%, operating margin is -84500.0%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -198.1%.
Is TCRT growing earnings?
Yes, TCRT earnings are accelerating — EPS growth of +24.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-4M. Earnings momentum is strengthening.
What was TCRT's best earnings year?
Alaunos Therapeutics, Inc.'s highest annual net income on record is $-35842.00, achieved in fiscal year 2003. Earnings history on this page spans 2001 to 2025 and includes all annual and quarterly figures.
What were TCRT's earnings last quarter?
TCRT's most recent reported quarter was Q1 2026. Net income was $-1M with diluted EPS of $-0.59. For a full breakdown of all quarters, see the quarterly earnings table on this page.